The US Drug Administration approves cannabis study with veterans. The FDA, the US Food and Drug Administration, is the Food and Drug Administration of the United States, and therefore the US Department of Health.
Now, the authority, previously conservative of cannabis, has for the first time approved a pilot study to investigate the effects of cannabis use in post-traumatic stress disorder in war veterans.
The US Drug Administration approves cannabis study with veterans
Placebo-controlled, triple-blind, randomized crossover pilot study on the safety and efficacy of four different potencies of smoked marijuana in 76 veterans with chronic, treatment-resistant post-traumatic stress disorder (PTSD) Sue Sisley led to the development of cannabis into a prescription drug by the FDA.
This could be a hope for the many war veterans who suffer as a result of their missions. Since September 2014, there are about 2.7 million American veterans of the Iraq and Afghanistan wars.
According to one study, at least 20% suffer from PTSD and / or depression. Recent studies show that the suicide rate is much higher than previously thought. About 22 people are killed each day.
The so-called MAPS study (Marijuana for Symptoms of PTSD in US Veterans) is carried out in Scottsdale, Arizona. Since March 15, 2017, the 76 participants are receiving cannabis from the National Institute for Drug Abuse (NIDA).
The study will investigate whether smoked marijuana in 76 US veterans with chronic, treatment-resistant post-traumatic stress disorder (PTSD) may help alleviate PTSD symptoms.
Participants must be US veterans, men or women, 18 years of age or older, diagnosed with PTSD who did not experience symptom improvement by taking medication or using psychotherapy.
Study Director Sue Sisley had already begun in 2009 with the preparation of the study. But only in March 2017, it came to a promise. Now all funds and approvals are available to carry out this important study.
The results of this study could significantly influence US health policy on cannabis as a medicine. The DEA (Drug Enforcement Administration), the drug regulatory agency, had already approved the study in 2016.